Compare · NVO vs TOVX
NVO vs TOVX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Theriva Biologics Inc. (TOVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TOVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 13931.5x TOVX ($14.1M).
- Over the past year, NVO is down 44.1% and TOVX is down 41.6% - TOVX leads by 2.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 3 for TOVX).
- NVO has more recent analyst coverage (25 ratings vs 0 for TOVX).
- Company
- Novo Nordisk A/S
- Theriva Biologics Inc.
- Price
- $43.97+2.76%
- $0.32+29.68%
- Market cap
- $196.28B
- $14.1M
- 1M return
- -6.43%
- -6.13%
- 1Y return
- -44.15%
- -41.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest TOVX
- Theriva Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
- Theriva Biologics Inc. filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by Theriva Biologics Inc.
- Theriva Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
- SEC Form DEF 14A filed by Theriva Biologics Inc.
- SEC Form PRE 14A filed by Theriva Biologics Inc.
- Theriva Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting